Responsive image ESS WEB CONFERENCE 2021 - PROGRAMME

Save this Event to your Calendar

Τimes shown are CET – Central European Time



10.00-11.00 Opening ceremony
Evangelos J. Giamarellos-Bourboulis, President ESS
Markus Huber-Lang, Past-President ESS
Marcin Osuchowski, President-Elect ESS

• Pandemics that change our World: the role of immune response
Jean-Marc Cavaillon (Paris, France)

• Shock research: Cassandra or Prometheus?
Markus Huber-Lang (Ulm, Germany)

• Shock research in our times

• Discussion with panelists from International Federation of Shock Societies
Athanasios Chalkias (Larissa, Greece)
Reinaldo Salomao(Sao Paolo, Brazil)
Xy Ben Lu (Beijing, People’s Republic of China)

11.00-12.30 Basic research in shock and sepsis
Moderator:Marcin Osuchowski (Vienna, Austria)

• How can minimal quality be achieved?
Daniel G. Remick (Boston, USA)

• The need to standardize the shock model
Andrea Szabó (Szeged, Hungary)

• How to implement clinically extrapolated endpoints in animal research
Marcin Osuchowski (Vienna, Austria)

• Disseminated intravascular coagulation and thrombosis: what does the animal setting suggest for the human host?
Nicole P. Juffermans (Amsterdam, The Netherlands)

• Discussion

12.30-13.00 Invited Lecture
Moderator: Evangelos J. Giamarellos-Bourboulis (Athens, Greece)

• Trained immunity and survival from critical illness
Mihai G. Netea (Nijmegen, The Netherlands)

13.00-13.30: Short break

13.30-14.45 Trauma and hemorrhage
Moderator: Marc Maegele (Cologne, Germany)

• Blood multiomics: new insights into the pathophysiology of shock
Federico Aletti (São Paulo, Brazil)

• How alcohol influences the host response to trauma and hemorrhage
Borna Relja (Magdeburg, Germany)

• Role of the endothelium and endotheliopathy
Marc Maegele (Cologne, Germany)

• Discussion

14.45-15.45 Syndrome of persistent inflammation after critical illness
Moderator: Stylianos Orfanos (Athens, Greece)

• After polytrauma
Rebecca Halbgebauer (Ulm, Germany)

• After severe sepsis
Philip A Efron (Florida, USA)

• Cardiovascular and molecular prognostic factors
Sina M. Coldewey (Jena, Germany)

• Discussion

15.50-18.00 COVID-19: From pathogenesis to therapy
Moderator: Joost W. Wiersinga (Amsterdam, The Netherlands)

• What is the role of antivirals in critical illness?
Andreas Barratt-Due (Oslo, Norway)

• C5a as treatment target
Alexander Vlaar (Amsterdam, The Netherlands)

• Early IL-1 inhibition
Evangelos J. Giamarellos-Bourboulis (Athens, Greece)

• Do all patients need corticosteroids?
Gilles Hayem (Paris, France)

• IL-6 pathway inhibitors
Hernando Gomez (Pittsburgh, Pennsylvania)

• Cell therapy
Antonio Artigas (Barcelona, Spain)

• Discussion

18:00 General Assembly of the European Shock Society

08:30-09:00 SHOCKingly fast: Host response diagnostics in clinical practice for sepsis and acute infection
Moderator: Evangelos J. Giamarellos-Bourboulis (Athens, Greece)
Purvesh Khatri (San Francisco, California)

Satellite lecture sponsored by Inflammatix

09.00-12.00 The European Shock Society meets the ImmunoSep consortium for personalized sepsis treatment
Moderators:G. Netea (Nijmegen, The Netherlands) and Evangelos J. Giamarellos-Bourboulis (Athens, Greece)

• The ImmunoSep protocol of evaluation of personalized management
Peter Pickkers (Nijmegen, The Netherlands)

• Consult sepsis endotypes
Tom van der Poll (Amsterdam, The Netherlands)

• Progenitor and stem cells in sepsis
Tomasz Skirecki (Warsaw, Poland)

• T lymphocytes function and sepsis-induced immunosuppression
Stefanie B. Flohé (Essen, Germany)

• Should we care about personalized antimicrobial care?
George Dimopoulos (Athens, Greece)

• May transcriptomic profile change by treatment?
Joachim Schultze (Bonn, Germany)

• Challenges to enroll and follow-up patients
Frank Bloos (Jena, Germany)

• Challenges to monitor a trial of personalized treatment in the COVID pandemic
Antigone Kotsaki (Athens, Greece)

• SOFA score: measure of sepsis and measure of endpoint
Michael Bauer (Jena, Germany)

12.00-13.00 The European Shock Society meets the Global Sepsis Alliance and the European Sepsis Alliance
Moderators: Tex Kissoon (Vancoover, Canada) and Daniela Filipescu (Bucharest, Roumania)

• Strategies to decrease the burden of sepsis
Konrad Reinhart (Berlin, Germany)

• COVID-19 and sepsis: resemblances and differences
Ricardo Ferrer (Barcelona, Spain)

• The need of a European Registry
Christian S. Scheer

• Discussion

13.00-13.30: Short break

13.30-15.00 Biomarkers: can they really guide our daily practice? (in collaboration with the Hellenic Sepsis Study Group)
Moderators: Mark Clemens (North Carolina, USA) and Iraklis Tsangaris (Athens, Greece)

• Procalcitonin use and sepsis survival
Evdoxia Kyriazopoulou (Athens, Greece)

• Trust suPAR for COVID-19
Massimo Fantoni (Rome, Italy)

• Optical biosensor technology
Nikolaos Antonakos (Athens, Greece)

• CRP and ferritin
Gilles Kaplanski (Marseille, France)

• Should we surrogate viral load?
Francesco Veas (Marseille, France)

• Discussion

15.00-16.30 Emerging dilemmas in management
Moderator: Charalambos Gogos (Athens, Greece)

• Rapid molecular diagnosis of the pathogen
Vittorio Sambri (Bologna, Italy)

• Clarithromycin for the critically ill
Eleni Karakike (Athens, Greece)

• Ceftazidime/avibactam and ceftolozane/tazobactam: which drug for which patient?
Matteo Bassetti (Genova, Italy)

• How to treat severe pneumonia
Antoni Torres (Barcelona, Spain)

• Discussion

16:30-17:00 Host response based tools for managing acute infection
Moderator: Evangelos J. Giamarellos-Bourboulis (Athens, Greece)
Tanya Gottlieb (Tirat Carmel, Israel)

Satellite lecture sponsored by MeMed Diagnostics